Semi-annual Report for 2026
Filed with SSE · · 188 pages · Chinese
CanSino Biologics, Inc. on 6ix
Earlier from CanSino Biologics
- Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Performance Briefing
- Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on Obtaining Drug Registration Certificate for Adsorbed Tetanus Vaccine
- Announcement on Voluntary Disclosure of Acceptance of the Drug Registration Application for Adsorbed Tetanus, Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine (For Persons Aged 6 and Above)
- CanSino Biologics: CanSinoBIO's Menhycia® Application Accepted by China's NMPA for Expanded Use in Population Aged 3 Months to 17 Years
Later from CanSino Biologics
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Biological Products and CXO Industry
- Announcement on Granting Certain Reserved Restricted Shares to Participants under the 2025 A-Share Restricted Share Incentive Plan
- Announcement on Receipt of Government Subsidies
- (688185)"Cansino Biologics Inc."Announcement on Cancellation of Certain Granted but Unvested Restricted Shares
- (688185)"Cansino Biologics Inc."Announcement on Provision for Expected Credit Losses and Asset Impairment and Write-down of Certain Deferred Tax Assets for Q3 2026
Follow CanSino Biologics into a list and get an email when it puts out news.
Follow CanSino Biologics